Fixation of the Stereotactic Frame and of the Eyes
The stereotactic frame must be fixed in a position that enables easier irradiation of the eye, which requires the frame to be in an anterior position with an appropriate rotation. Every attempt is made to bring the eye to be treated close to the center of the stereotactic system. The treated eye was fixed by suturing two rectus muscles to the stereotactic frame. To ensure a build up and homogeneous propagation of radiation between tissues and the air, a partial tarsorrhaphy was performed and a gel-filled plastic cover was used. This also acted as protection for the cornea. 15, 16, 18 
Treatment Target
The images required for treatment planning were obtained from an MR imager (Magnetom Expert 1 tesla, Siemens). Gradient echo T 1 -weighted three-dimensional sequences and 1.3-mm slices were used.
The optimal radiation pattern was elaborated in three successive steps. 15, 18 Group I (six cases). Two segments of the ciliary body received low-dose irradiation. The 4-mm collimators were used. The center of the isodose was targeted inside the corpus vitreum so that the 50% isodose covered the ciliary body structures and was close to the lens. Two segments of the ciliary body were irradiated with 14 Gy to the 50% isodose using 2 ϫ 3 isocenters as illustrated in Fig. 1 .
Group II (eight cases). Because there were no significant side effects in Group I and because the effect of the treatment seemed less than optimal, a new strategy was devised.
The whole ciliary body was irradiated in a circular manner with 20 Gy to the 50% isodose line (Fig. 2) . This circular volume surrounding the lens was achieved with seven to eight 4-millimeter collimators. The results of the GKS were better and the period to symptomatic improvement was shorter than in Group I. There were moreover no signs of increased radiotoxicity; however, because the treatment time was approximately 60 minutes many patients suffered discomfort, especially those who were elderly. Thus, it was determined that a shorter treatment time was important.
Group III (88 cases). The final radiation pattern was adapted so that the entire ciliary body was incorporated into the target, which was covered with lower number of larger collimators (Fig. 3) . Four isocenters of 8-mm collimator were displaced in such a way that the lens was mostly spared, and, in addition to the ciliary body, the enlarged radiation volume encompassed the relatively radiation-tolerant structures of the anterior ocular segment We kept the radiation dose at the same level as in the second pilot group-20 Gy at the 50% isodose-for blind patients and 15 Gy for patients with some preserved vision.
Follow-Up Review
The patients were followed by an ophthalmologist at regular 3-month intervals during for the 1st year after GKS and twice yearly thereafter. The same ophthalmological examination was performed as before GKS. The three main symptoms documented were pain, IOP, and neovascularization. 
Results

Treated Patients
Between February 1999 and August 2003 105 patients were treated for advanced glaucoma. Three patients were lost to the follow up. One died of unknown causes and two refused to attend follow up. One hundred and two patients were treated and monitored (total number of irradiated eyes 106). The median follow-up period was 20 months (range 2-54 months). The demographic data are presented in Table  1 . All patients had a long history of the disease, had exhausted all kinds of conventional therapy, had remained refractory to all treatments, and were suffering progressive severe damage of vision.
A complete clinical eye examination was performed. During the study, the conventional examination methods were expanded to include ultrasonic biomicroscopy and ocular blood flow. These methods enable postirradiation changes in target structures and some pathophysiological parameters to be followed.
There were 30 patients with primary open angle glaucoma and 72 with secondary glaucoma.
Pilot Group I
In Pilot Group I six patients received treatment with a median volume of 627 mm 3 (range 313-1000 mm 3 ). They all suffered from severe pain, elevated median IOP of 48.5 mm Hg (range 25-55 mm Hg), and had considerable neovascularization.
Four patients showed marked improvement after GKS: pain disappeared in three and remained mild in one. Their IOP was lowered to a median of 20 mm Hg (range 20-43 mm Hg). The neovascularization regressed noticeably. All these changes were observed after a latency of approximately 20 months, and there were no significant radiotoxic side effects. Irradiation failed in two patients. One suffered from continuing pain and increased IOP. He insisted on enucleation of the eye, which had been one of the alternative treatments considered before irradiation. The enucleation was performed. Histological examination showed atrophy of the ciliary body (Fig. 4) . One patient who improved only slightly was included into the Pilot Group II because the higher-dose ciliary body circular irradiation would have a better chance of a more pronounced effect.
Pilot Group II
Ten eyes in nine patients were irradiated, one patient bilaterally. The median irradiated volume was 890 mm 3 (range 467-1000 mm 3 ). The circular ciliary body irradiation and slightly elevated radiation dose improved the effects of treatment effect. Pain, which was medium to severe, disappeared in all patients after a median interval of 8 weeks. The IOP dropped from a median of 45 mm Hg (range 36-55 mm Hg) to a median of 20 mm Hg (range 17-30 mm Hg) after a median of 12 weeks. When neovacularization was present, it diminished by at least one degree during a median of 18 weeks. All patients in this group improveed after GKS.
Pilot Group III
There were 88 patients in whom 91 eyes were irradiated.
V. Vladyka, et al. Table 2 ). The radiation planning was modified as outlined above and this treatment method is currently our definitive radiosurgical treatment for advanced refractory glaucoma. The irradiated volume was enlarged to a median of 2900 mm 3 (range 1100-3800 mm 3 ). Pain was present before irradiation in all patients treated for secondary glaucoma and was in the majority (93%) intense Grade II to III (Table 3 ). It disappeared in 47 patients (77%). Seven patients suffered Grade I residual pain for which no medication was required. Three patients had Grade II pain and required some analgesic agents, and in four patients the pain was not improved. Pain was not a prominent symptom in primary open angle glaucoma (Table 3) . Five patients (19%) in this group had Grade I and II pain before irradiation. Three of them suffered no further pain after GKS and two improved to not needing medication. The median period to the analgesic effect was 6 weeks (range 2-32 weeks).
The IOP was also more elevated before irradiation in patients with secondary glaucoma than in those with primary open angle glaucoma (Table 4 ). In secondary glaucoma the median IOP was 51.3 mm Hg (range 23-68 mm Hg) but after GKS the median value fell to 27 mm Hg (range 8-48 mm Hg). In primary open angle glaucoma the less raised IOP also fell from a median of 25.3 mm Hg (range 17-35 mm Hg) to 16.1 mm Hg (range 12-28 mm Hg). The latency period for improved IOP was 12 weeks (range 2-74 weeks), which is twice as long as the period to pain relief.
In the 40 patients suffering from neovascular glaucoma a reduction in neovascularization was observed in 27 patients.
In 31 (50.8%) patients with secondary glaucoma who underwent GKS the IOP remained elevated and in seven of 61 patients with Grade II or III pain residual pain was present at the same level. When the clinical status was satisfactory there was no need for further intensive treatment. In 29 patients (47.5%), however, combined antiglaucomatous and analgesic pharmacotherapy, and in 12 patients (19.7%), laser cyclocoagulation was required. No additional trabeculectomy had to be renewed and no other patient apart from the first pilot group member needed enucleation of the bulb.
Treatment Complications
Treatment complications were not serious. Lacrimation was an early symptom after GKS. It was noticed in 61% of treated patients for few days to 1 week and was related to the minor trauma caused by fixation of the eye and the moderate lid edema after tarsorrhaphy.
The radiation dose to the lens was so high that postirradiation cataract had to be expected. In addition, most patients had different stage of cataract already before irradiation. Thirty-one had pseudophakia and four had aphakia. In two patients the cataract advanced during the follow-up period to the extent that the cataract extraction and implantation of posterior chamber lens had to be performed.
Keratopathy was present in 34 eyes before GKS, and we observed no deterioration after treatment. Two new patients suffered from noninfectious (mechanical) keratitis.
At the beginning of our clinical study, ocular radiotoxicity was evaluated using the RTOG and EORTC scoring systems 12 in a group of 35 consecutive patients. The results will be presented separately.
Discussion
The generally accepted current view of the pathophysiology of glaucoma is that a progressive loss of ganglion cells causes visual field damage related to the raised IOP. 10 The goal of radiosurgical treatment depends on the stage of the disease. When vision is totally or partially lost the main aim is to abolish the elevated IOP and to eliminate severe pain. In the early stages of the disease, when conventional therapy has failed and visual acuity is still preserved, the treatment has the more difficult task of preventing any further Status  0  I  II  III  0  I  II  III   pre-GKS  22  3  2  0  0  4  11  46  post-GKS  25  2  0  0  47  7  3  4 * The median latency period after GKS was 6 weeks (range 2-32 weeks). progression of the pathogenic mechanisms. Although many clinicians now believe that there are several factors involved in the pathogenesis of glaucoma, the only rigorously proven treatment method is the lowering of IOP.
11
Glaucoma was first considered to be a surgical disease. The first study comparing the two available forms of glaucoma treatment, eserine and iridectomy, was performed at Wills Eye Hospital in 1895 by Zentmayer, et al. 20 This study showed that both treatments were equally effective and that a patient's visual status could be maintained for periods ranging from 5 to 15 years by undertaking chronic medical treatment. The debate over which is the best therapy is ongoing. Most clinicians use medication as the initial treatment for glaucoma. In the US, two major studies were performed to compare medical treatment with trabeculoplasty (Glaucoma Laser Trial) and medical treatment versus trabeculectomy (CIG). After 2 years of follow up in the Glaucoma Laser Trial, the eyes that had received argon laser trabeculoplasty showed a lower mean IOP (by 1-2 mm Hg) compared with eyes started on timolol, but showed no difference either in the extent of the visual field or in acuity.
At 7 years, eyes that had received argon laser trabeculoplasty showed a greater reduction in IOP (by 1.2 mm Hg) and greater sensitivity in the visual field (0.6 dB). Interim 5-year results of the CIGT study showed no difference in the visual field despite a lower IOP in the surgical group. Visual acuity and local eye symptoms seem to be more influenced in the surgical group. To date, the CIGT results do not yet support changing the current paradigm of medication as the initial treatment; however, longer-term follow-up data are needed to enable more conclusive recommendations for a chronic disease such as glaucoma.
Patients whose glaucoma is still not controlled after medical, laser, and incisional surgical interventions are usually candidates for a cyclodestructive procedure like cyclocryotherapy, which freezes and destroys part of the ciliary body to decrease the production of aqueous humor. 17 An alternative to cyclocryotherapy is cyclophotocoagulation, which uses laser to destroy the ciliary body. The laser energy, like the freezing, passes through the full thickness of the conjunctiva and the sclera and destroys the ciliary body beneath; however the "innocent tissues" lying over the ciliary body are often damaged in these methods. To avoid damage we started to use GKS. It has the advantage of a being a noninvasive radiosurgical method with precise and selective targeting of pathogenically important eye structures. Thus, side effects can be avoided or minimized. The procedure causes no strain for the patient and is performed on an outpatient basis.
Gamma knife surgery of the ciliary body leads to a significant alleviation of pain and reduction of IOP in advanced glaucoma. It is effective in secondary glaucoma, especially when neovascularization is present. 15, 18 The latency of the treatment effect is relatively short. The patients with primary open angle glaucoma suffer less pain, their IOP is less elevated, and their disease is mainly expressed by visual loss as a manifestation of the optic neuropathy. Even in the early stages of glaucoma, this can be detected by confocal laser scanning tomography and nerve fiber layer testing and analysis. [4] [5] [6] 9, 13 The treatment effect on the optic neuropathy can be evaluated after a longer follow-up period by registering visual function and performing other tests for glaucoma neuropathy. We have assumed that GKS can help to prevent further progression of optic neuropathy, but a longer follow-up period is needed to evaluate this hypothesis. Special ophthalmological examinations must be performed to make this evaluation. A prospective 5-year clinical study to assess the cessation of progressive optic neuropathy in the early stages of glaucoma is under way.
In this series, when there was improvement, it lasted throughout the follow-up period and pharmacotherapy could be gradually tapered in all patients and stopped in approximately one third. There has been no recurrence of symptoms that improved so far. There has also been no deterioration in vision but the follow-up period is not yet long enough to determine the significance of this observation.
Conclusions
Gamma knife surgery is a noninvasive procedure that can improve raised IOP, pain, and neovascularization in patients with advanced glaucoma when conventional therapy fails. Radiosurgery in advanced glaucoma may be preferable to invasive surgical treatment.
